About us
SIGNIA Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for […]
Respiratory infections
Acute respiratory tract infection Acute respiratory tract infections (ARTI) represent the main cause of acute diseases worldwide and remain the number one cause of deaths in newborns and young children (nearly 2 million deaths/year). Respiratory pathogens represent a major public health issue and have a large socio-economic impact. ARTI caused by several viruses including influenza […]
Innovative Science & Technology
To identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication Signia Therapeutics initial strategy focuses on the identification and repurposing of already FDA-approved drugs for new antiviral indication. The Company’s proposes a novel strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs for […]
Team
President Michel Cousineau (MBA) has over 35 years of experience in corporate and business development in the health care sector for emerging companies as well as with subsidiaries of large international biopharmaceutical companies. He brings a vast network of contacts throughout the industry at various level of management and with investment groups. […]
Our Blog
Signia Therapeutics will participate to the 21st edition of the Venture 5i (Grenoble 30-31 May 2018)
Nous avons le plaisir d’annoncer que SIGNIA THERAPEUTICS a été sélectionné pour présenter et participer à la 21ème édition du Venture 5i qui aura lieu les 30 et 31 mai 2018 au WTC Grenoble. La présentation se fera devant les investisseurs le 30 Mai à 18h15 et la compagnie participera aux One2One meetings avec les […]
Read More
Signia Therapeutics will be present at BIO 2018 Boston (4-7 June 2018)
Signia Therapeutics is please to announce that it will have several activities during the BIO 2018 that will be held in Boston from June 4 to June 7 2018. As the world’s largest biotechnology event, the BIO International Convention provides several specialized opportunities geared towards start-up and emerging companies. Signia Therapeutics has been selected to […]
Read More
EU H2020 Seal of Excellence for Signia Therapeutics
We are very proud to announce that Signia Therapeutics has been awarded the Seal of Excellence by the EU H2020 Framework Programme for Research and Innovation.
Read More
Signia Therapeutics will participate to major partnering events in February/March 2018
Signia Therapeutics will participate to two major partnering events in February/March 2018 11th Annual European Life Science CEO Forum, in Zurich (26-27 February 2018) http://www.sachsforum.com/11elsceo-about.html 12th Annual International Partnering Conference BIO-Europe SPRING (12-14 March 2018) https://ebdgroup.knect365.com/bioeurope-spring/
Read More
Signia Therapeutics annonce un accord majeur de licence et le lancement d’un essai de phase 2
Lyon, le 22 Janvier 2018 Signia Therapeutics annonce un accord majeur de licence et le lancement d’un essai de phase 2 La start-up Signia Therapeutics vient de signer un accord majeur de licence avec l’Université Claude Bernard de Lyon (UCBL) et l’Université Laval à Québec afin d’acquérir les droits internationaux d’exploitation exclusive de trois brevets […]
Read More
SIGNIA THERAPEUTICS ANNOUNCES ACHIEVEMENT OF CORPORATE MILESTONES
SIGNIA THERAPEUTICS ANNOUNCES ACHIEVEMENT OF CORPORATE MILESTONES LYON, FRANCE (November 28, 2017) – Signia Therapeutics is an emerging company, spin-off company of VirPath laboratoy/Université Claude Bernard Lyon (UCBL), that proposes an innovative and versatile platform for antiviral drug discovery and repositioning or recycling based on a global targeting of the host cell instead of specific […]
Read More
SIGNIA Therapeutics laureate of i-Lab 2017 award
We are very proud to announce that Signia Therapeutics is laureate of the i-Lab 2017 award from the French Ministry of Higher Education, Research and Innovation, and BpiFrance. The i-Lab is a national competition open to all French start-ups designed to identify the most promising technical innovations by France’s most forward-thinking start-ups. The award is […]
Read MoreSIGNIA therapeutics - Copyright 2018 - Corporate Lite theme by Flythemes
